Canopy Growth shares were falling Friday, following a downgrade from Bank of America.
Bank of America analysts lowered their rating on the cannabis company’s shares to neutral from buy. The bank also slashed its price target to $27 from $46 - the latter being a slight upside from the stock's closing price Thursday of $27.74.
Bank of America analyst Christopher Carey is hopeful of Canopy’s long-term potential to be a leader in the burgeoning global cannabis market. However, he is also wary of near-term risks for the stock. Carey indicated that there is excessive risk in Canopy shares if estimates remain at their current levels. His views have considered the current situation of the Canadian cannabis market. Health risks like respiratory problems that are being associated with vaping is a headwind to cannabis stock sentiment, as hinted by Carey.
Meanwhile, consensus analyst expectations are pointing towards double-digit quarter-over-quarter revenue growth from Canopy in the second half of 2019.